Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

Open access
Voloshin, Tali, Kaynan, Noa, Davidi, Shiri, Porat, Yaara, Shteingauz, Anna, Schneiderman, Rosa S., Zeevi, Einav, Munster, Mijal, Blat, Roni, Tempel Brami, Catherine, Cahal, Shay, Itzhaki, Aviran, Giladi, Moshe, Kirson, Eilon D., Weinberg, Uri, Kinzel, Adrian, Palti, Yoram · 2020 · Cancer Immunology, Immunotherapy

Abstract

Tumor-treating fields (TTFields) are alternating electric fields in a specific frequency range (100–300 kHz) delivered to the human body through transducer arrays. In this study, we evaluated whether TTFields-mediated cell death can elicit antitumoral immunity and hence would be effectively combined with anti-PD-1 therapy. We demonstrate that in TTFields-treated cancer cells, damage-associated molecular patterns including high-mobility group B1 and adenosine triphosphate are released and calreticulin is exposed on the cell surface. Moreover, we show that TTFields treatment promotes the engulfment of cancer cells by dendritic cells (DCs) and DCs maturation in vitro, as well as recruitment of immune cells in vivo. Additionally, our study demonstrates that the combination of TTFields with anti-PD-1 therapy results in a significant decline of tumor volume and increase in the percentage of tumor-infiltrating leukocytes in two tumor models. In orthotopic lung tumors, these infiltrating leukocytes, specifically macrophages and DCs, showed elevated expression of PD-L1. Compatibly, cytotoxic T-cells isolated from these tumors demonstrated increased production of IFN-γ. In colon cancer tumors, T-cells infiltration was significantly increased following long treatment duration with TTFields plus anti-PD-1. Collectively, our results suggest that TTFields therapy can induce anticancer immune response. Furthermore, we demonstrate robust efficacy of concomitant application of TTFields and anti-PD-1 therapy. These data suggest that integrating TTFields with anti-PD-1 therapy may further enhance antitumor immunity, hence achieve better tumor control.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-020-02534-7

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 179

Metadata

Authors
Voloshin, T., Kaynan, N., Davidi, S., Porat, Y., Shteingauz, A., Schneiderman, R. S., Zeevi, E., Munster, M., Blat, R., Tempel Brami, C., Cahal, S., Itzhaki, A., Giladi, M., Kirson, E. D., Weinberg, U., Kinzel, A., & Palti, Y.
Venue
Cancer Immunology, Immunotherapy
Published
2020-03-06
Volume
69
Issue
7
Pages
1191-1204
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W3009856270
Cited by
179
References
19
FWCI
6.58
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. https://app.cochat.ai/papers/10.1007/s00262-020-02534-7
The paper
Voloshin, T., Kaynan, N., Davidi, S., Porat, Y., Shteingauz, A., Schneiderman, R. S., Zeevi, E., Munster, M., Blat, R., Tempel Brami, C., Cahal, S., Itzhaki, A., Giladi, M., Kirson, E. D., Weinberg, U., Kinzel, A., & Palti, Y. (2020). Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-020-02534-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.